{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Oriol-Tordera B"],"funding":["NIAID NIH HHS","Medical Research Council"],"pagination":["103956"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8938861"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["78"],"pubmed_abstract":["Background
The BCN02-trial combined therapeutic vaccination with a viral latency reversing agent (romidepsin, RMD) in HIV-1-infected individuals and included a monitored antiretroviral pause (MAP) as an efficacy read-out identifying individuals with an early or late (< or > 4weeks) viral-rebound. Integrated -omics analyses were applied prior treatment interruption to identify markers of virus control during MAP.Methods
PBMC, whole-genome DNA methylation and transcriptomics were assessed in 14 BCN02 participants, including 8 Early and 4 Late viral-rebound individuals. Chromatin state, histone marks and integration analysis (histone-3 acetylation (H3Ac), viral load, proviral levels and HIV-specific T cells responses) were included. REDUC-trial samples (n = 5) were included as"],"journal":["EBioMedicine"],"pubmed_title":["Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome."],"pmcid":["PMC8938861"],"funding_grant_id":["MR/N023668/1","P01 AI131568"],"pubmed_authors":["Hanke T","Paredes R","Sanchez-Pla A","Tolstrup M","Esteller M","Llano A","Berdasco M","Goncalves E","Duran-Castells C","Catala-Moll F","Cedeno S","Molto J","Martinez-Picado J","Combadiere B","Esteve-Codina A","Sogaard OS","Mothe B","Calle ML","Ruiz-Riol M","Rosas-Umbert M","Clotet B","Oriol-Tordera B","Puertas MC","Hartigan-O'Connor D","Brander C","Meulbroek M"],"additional_accession":[]},"is_claimable":false,"name":"Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome.","description":"Background
The BCN02-trial combined therapeutic vaccination with a viral latency reversing agent (romidepsin, RMD) in HIV-1-infected individuals and included a monitored antiretroviral pause (MAP) as an efficacy read-out identifying individuals with an early or late (< or > 4weeks) viral-rebound. Integrated -omics analyses were applied prior treatment interruption to identify markers of virus control during MAP.Methods
PBMC, whole-genome DNA methylation and transcriptomics were assessed in 14 BCN02 participants, including 8 Early and 4 Late viral-rebound individuals. Chromatin state, histone marks and integration analysis (histone-3 acetylation (H3Ac), viral load, proviral levels and HIV-specific T cells responses) were included. REDUC-trial samples (n = 5) were included as","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2026-06-01T02:09:42.73Z","creation":"2025-04-05T09:49:34.267Z"},"accession":"S-EPMC8938861","cross_references":{"pubmed":["35325780"],"doi":["10.1016/j.ebiom.2022.103956"]}}